Metoprolol Tartrate Market - Forecast(2024 - 2030)

Metoprolol Tartrate Market Overview

Metoprolol Tartrate Market size is estimated to reach $868.3 million by 2027, growing at a CAGR of 5.2% during the forecast period 2022-2027. The medication metoprolol tartrate, frequently recognized as metoprolol, is utilized to treat hypertension (high blood pressure). Metoprolol is a beta-blocker, which is a class of medications. Metoprolol is accessible as two distinct salts: metoprolol tartrate and metoprolol succinate. These two salts are not interchangeable because they have different dosages, durations of action and indications for application. The activity of certain natural substances in the body, like epinephrine, on the blood vessels and heart, is blocked by this medicine. This effect decreases blood pressure, heart rate and cardiac strain. This medication is also used to treat angina (chest pain) and to help people live longer after a heart attack. It works by slowing down the heart rate and makes the heart more efficient at pumping blood around the body. In eight hypertensive diabetic subjects accepting hydrochlorothiazide, glucose homeostasis as evaluated by the alterations in plasma glucose, insulin and glucagon after an oral glucose load was not essentially influenced by 8 weeks of therapy with metoprolol. When taking metoprolol prolonged-release tablets, the risk of a carbohydrate metabolism disorder or masking of hypoglycemia symptoms is lower than when using standard beta1 selective beta-blocker tablet forms and much lower than when using nonselective beta-blockers. Beta-adrenergic blocking drugs (beta-blockers) like carvedilol, propranolol, Hydrochlorothiazide and Atenolol, in metoprolol tartrate, are used to treat high blood pressure (hypertension) and congestive heart failure. Metoprolol tartrate reduces the frequency and severity of the attacks and the need for glyceryl trinitrate relief and increases exercise tolerance. Vasodilator agents acting on adenosine A2A receptors, like dipyridamole, adenosine and regadenoson, or inotropic agents, like dobutamine, may be utilized in pharmacologic stress testing. Metoprolol tartrate is a beta-adrenergic receptor blocking agent. In vitro and in vivo animal investigations have demonstrated that it has a preferential impact on beta-adrenoreceptors, principally situated in cardiac muscle.

With the expanding population of the elderly, Propranolol Hydrochloride Extended-Release Capsules are indicated in the management of hypertension and awareness and accessibility of Metoprolol Tartrate are set to drive the Metoprolol Tartrate Market. The increasing predominance of cardiovascular ailments and the emerging sedentary lifestyle are set to propel the growth of the Metoprolol Tartrate Industry during the forecast period 2022-2027. This represents the Metoprolol Tartrate Industry Outlook.

Metoprolol Tartrate Market Report Coverage

The “Metoprolol Tartrate Market Report - Forecast (2022-2027)", by Industry ARC, covers an in-depth analysis of the following segments in the Metoprolol Tartrate Market.

Key Takeaways

Metoprolol Tartrate Market: Market Share (%) By Region, 2021

Metoprolol Tartrate Market Segment Analysis - by Type

The Metoprolol Tartrate Market based on type can be further segmented into Oral and Injectable. The Oral Segment held the largest Metoprolol Tartrate market share in 2021. This growth is owing to the surging intake of oral forms of Metoprolol Tartrate tablets by mature grown-ups attributed to tablets being effortless to consume and accessible easily. Metoprolol Tartrate is a generic prescription medication that can be used with or without other medications to treat high blood pressure. Metoprolol is a beta-adrenergic receptor blocking agent. Metoprolol is also indicated for the treatment of hypertension, angina pectoris and myocardial infarction. Metoprolol Tartrate is a beta-blocker that influences the heart and circulation (blood flow by way of arteries and veins). the oral bioavailability of metoprolol is 40-50%. The regular intake of this medicine as prescribed to avert chest pain, a second heart attack or migraine headaches is further propelling the growth of the Oral segment.

Furthermore, the Injectable segment is estimated to grow with the fastest CAGR of 7.3% during the forecast period 2022-2027 owing to Metoprolol tartrate injection being a beta-adrenergic receptor blocking agent indicated for the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to decrease cardiovascular mortality when utilized in conjunction with oral metoprolol maintenance therapy. Metoprolol Tartrate Injectable is utilized for Blood pressure, Myocardial infarction, Hypertension, Angina pectoris and other conditions. Metoprolol injection is utilized at the time of the early stage of a heart attack to minimize the chance of loss of life, further fuelling the growth of the Injectable segment.

Metoprolol Tartrate Market Segment Analysis - by Application

The Metoprolol Tartrate market based on the application can be further segmented into Hypertension, Cardiovascular Diseases and Others. The Hypertension Segment held the largest Metoprolol Tartrate market share in 2021. This growth is owing to the surging application of Metoprolol Tartrate for the treatment of hypertension or high blood pressure. As per World Health Organization (WHO), approximately 1.28 billion mature grown-ups aged 30-79 years globally have hypertension, most (two-thirds) residing in low- and middle-income countries. Carvedilol is a medication utilized for treating hypertension (high blood pressure). Metoprolol tartrate is a beta-adrenergic receptor blocking agent. Metoprolol Tartrate and Hydrochlorothiazide tablet are accessible as tablets for oral administration. Metoprolol belongs to a category of medications termed beta-blockers, owing to the obstruction of the impacts of adrenaline on the beta receptors of the body, thereby slowing nerve impulses that journey by way of the heart. In that way, metoprolol calms the blood vessels and delays the heart rate to enhance blood flow and decrease blood pressure which is further propelling the growth of this segment.

Furthermore, the Cardiovascular Diseases segment is estimated to grow with the fastest CAGR of 6.4% during the forecast period 2022-2027 owing to Metoprolol being a beta-blocker, principally utilized to treat cardiovascular conditions like high blood pressure and heart failure. It is among the most commonly prescribed beta-blockers. Carvedilol is utilized for treating angina (heart-related chest pain) and heart failure. As per World Health Organization (WHO), approximately 17.9 million people lost their lives from cardiovascular diseases (CVDs) in 2019, depicting 32% of all worldwide demises. Beta-blockers work by preventing hormones that increase blood pressure from binding to receptors, which helps increase blood flow and reduces blood pressure. The application of Metoprolol Tartrate assists in averting future heart attacks and stroke which is further fuelling the growth of this segment. 

Metoprolol Tartrate Market Segment Analysis - by Geography

The Metoprolol Tartrate market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Metoprolol Tartrate Market) held the largest Metoprolol Tartrate market share with 36% of the overall market in 2021. This is owing to the increasing predominance of heart ailments in the North American region. Several companies are adopting strategies, such as product launch and expansion and inorganic growth strategies, including partnerships and collaboration. These growth strategies have supported the market players in growing their business and enhancing the growth in Metoprolol Tartrate. As per World Health Organization (WHO), out of the 17 million premature deaths (under the age of 70) owing to noncommunicable diseases in 2019, 38% were brought about by cardiovascular diseases (CVDs). However, hospitals and other medical institutions have resumed normal operations with extreme caution and patient visits for other ailments have also restarted. The rising growth in the pharmaceutical industry drives R&D activities pertaining to medications, which is further propelling the growth of the Metoprolol Tartrate Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the expanding application of Metoprolol Tartrate to treat hypertension or high blood pressure and angina (heart-associated chest pain) in the Asia-Pacific region. "The effective dosage range of Metoprolol Tartrate Tablets USP is 100 mg to 400 mg per day". Metoprolol tartrate is a beta-adrenergic receptor blocking agent. The heightening application of propranolol for the treatment of heart and brain ailments and the application of Metoprolol Tartrate for averting migraine are further fuelling the growth of the Metoprolol Tartrate Industry in the Asia-Pacific region.

Surging Applications of Metoprolol Tartrate are Propelling the Growth of the Metoprolol Tartrate Industry

Carvedilol is utilized to treat hypertension. Like Propranolol, Metoprolol Tartrate belongs to a category of medications termed beta-blockers. It is utilized to treat high blood pressure (hypertension), angina (heart-associated chest pain) and irregular heart rhythms (arrhythmia). It also assists in averting future heart attacks and strokes and to avert migraine. It is also utilized to decrease the hazard of loss of life or requiring to be hospitalized for heart failure. Metoprolol is utilized with or without additional medicines to treat high blood pressure (hypertension). Lowering high blood pressure assists in averting strokes, heart attacks and kidney issues. This medicine is also required to treat chest pain (angina) and to enhance survival subsequent to a heart attack. Atenolol also belongs to the class of medicines termed beta-blockers. It is also utilized to treat high blood pressure (hypertension), angina (heart-related chest pain) and irregular heart rhythms (arrhythmia). Propranolol assists in reducing anxiety and alleviating tremors. Metoprolol performs by obstructing the activity of some natural chemicals in the body, like epinephrine, on the heart and blood vessels. This impact decreases the heart rate, blood pressure and strain on the heart. Metoprolol Tartrate Tablets, USP are accessible including 25 mg, 50 mg or 100 mg of metoprolol tartrate USP. The surging applications of Metoprolol Tartrate are therefore propelling the growth of the Metoprolol Tartrate Industry, thereby contributing to the Metoprolol Tartrate Industry Outlook, during the forecast period 2022-2027.

The Growing Advancement in Pharmaceutical Industry is Propelling the Growth of the Metoprolol Tartrate Market

The pharmaceutical industry is one of the most dynamic and diverse sectors, responsible for the production, development and marketing of medications and medical devices. Atenolol, carvedilol and propranolol are antihypertensive medications that form the beta-blocker class, which is extensively utilized in the treatment of hypertension and some other ailments. The pharma industry holds immense importance in the healthcare community, for its life-saving medical innovation and manufacturing. The very presence of the industry in the frontline of healthcare adds value to patient care services and healthcare accessibility. However, the industry is heavily-regulated with complex policies to ensure the quality, safety and efficacy of the medications. In recent years, the rapid technological advances and major breakthroughs in research have paved the way for the global pharmaceutical industry to bring forth better, faster and more affordable drug discovery and development processes. The continued growth in the biologics field, improvements in drug manufacturing and the increasing efficiency in disease control would add substantial accretion to the pharma industry valuations. As per www.incestindia.gov.in, India is the biggest provider of generic medicines worldwide, occupying a 20% share in global supply by volume and is the leading vaccine maker worldwide. India also has the greatest count of U.S.-FDA-compliant Pharma plants outside of the U.S. and is home to greater than 3,000 pharma firms with a robust network of over 10,500 manufacturing facilities and a greatly skilled resource pool. The pharmaceutical industry in India provides 60,000 generic brands across 60 therapeutic categories. This kind of advanced pharmaceutical industry in countries like India is further propelling the growth of the Metoprolol Tartrate Market during the forecast period 2022-2027.

Metoprolol Tartrate Market Challenges

Limitations of Metoprolol Tartrate are Hampering the Growth of the Metoprolol Tartrate Market

1. Novartis International AG
2. AstraZeneca PLC
3. Teva Pharmaceutical Industries
4. Changzhou Siyao Pharmacy Limited Company
5. Shanghai Sine Promod Pharmaceutical Corp. Ltd.
6. Sun Pharmaceutical Industries Ltd.
7. ZheJiang Apeloa JiaYuan Pharmaceutical Co. Ltd.
8. Guangzhou Hanfangare Pharmaceutical Co. Ltd.
9. Mylan N.V.
10. Bristol Laboratories Ltd.

• In December 2021, Novartis declared that it entered into a definitive agreement to gain all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Geographic atrophy (GA) is a progressive form of dry age-related macular degeneration (AMD) that results in progressive and irreversible vision loss. There are no certified treatments for GA, making it one of the most vital unmet requirements staying in retinal ailments.

• In July 2021, AstraZeneca finished the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the gain marks the firm’s entry into medicines for rare diseases and the starting of a novel chapter for AstraZeneca. AstraZeneca presently has an improved scientific presence in immunology and by way of, Alexion’s innovative complement-biology platform and strong pipeline, will continue to pioneer the discovery and development of medicines for patients with rare diseases. AstraZeneca acquired Alexion to design a novel strategic R&D center. 

• In January 2020, Novartis AG declared that it has finished the acquisition of The Medicines Company (the “Company”) by way of the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company continuing on the merger, without a vote of the Company’s stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. Over 50 million secondary prevention patients globally with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on the present standard of care do not accomplish the LDL cholesterol (LDL-C) objective and stay at the raised hazard of cardiovascular events. The Medicines Company proposed the New Drug Application (NDA) for inclusion in the FDA in December 2019. 

Relevant Reports:

Cardiology Surgical & Interventional Cardiology Devices Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code - HCR 0017

Drug Delivery Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code - HCR 0064

Pharmaceutical Packaging Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code - HCR 0039

For more Lifesciences and Healthcare Market reports, please click here